The application of computational modeling and simulation has extended beyond PK/PD prediction of clinical trial outcomes by defining regulatory strategy as well as optimization of therapeutic candidates. Further, regulatory agencies are accepting modeling and simulation for approval in special populations, drug–drug interactions, and dosing regimen changes. This volume provides a comprehensive coverage of drug design, chemoinformatics, molecular modeling, and computer-aided formulation development. Computer simulations play a crucial role in the pharmaceutical industry, accelerating drug discovery and development by predicting drug behavior and optimizing systems, thus reducing the need for animal testing.
Key Features
- Illustrates how computer simulations play a crucial role in the pharmaceutical industry, accelerating drug discovery and development.
- PK/PD simulations play a crucial role in optimizing dosing regimens and understanding the time course of drug effects.
- Depicts the role of computers in drug research development, both in clinical and preclinical stage by citing examples of approved FDA drugs.
- Provides case studies detailing the step-by-step process for using software such as Python for programming in the pharmaceutical industry; Gromacs, DataWarrior, AutoDock and Biovia.
- Discusses how artificial intelligence and machine learning can be used to optimize and refine simulation models.
Maksa helposti kortilla, Klarnalla, Apple Paylla tai Google Paylla. Etkö ole tyytyväinen? Sinulla on aina 14 päivän palautusoikeus. Lue lisää ehdoistamme. Jos sinulla on kysyttävää, lähetä meille sähköpostia osoitteeseen hello@memmo.org.
Memmo tekee opiskelusta helpompaa – missä päin maailmaa ikinä oletkin. Meillä yhdistät kurssikirjat ja fiksut opiskelutyökalut yhteen paikkaan: tiivistelmät, visat, podcastit ja muistikortit. Ja sitten Ted, opiskelukaverisi, joka vastaa kaikkeen, mitä ikinä mietitkin. Yli 50 000 opiskelijaa opiskelee jo täällä – rakennettu auttamaan sinua oppimaan nopeammin ja stressaamaan vähemmän.